This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

46/100

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Pattern expression strengths predicted amyloid status with a sensitivity of 0.94 and a specificity of 0.83. A support vector machine classification based on pattern expression strengths in 2 different SSM/PCA components yielded a prediction accuracy of 98%. Anatomically, prediction performance was driven by parietooccipital gray matter in amyloid-positive patients versus predominant white matter binding in amyloid-negative patients. SSM/PCA-derived binding patterns of 18 F-flortaucipir differentiate between amyloid-positive and -negative neurodegenerative diseases with high accuracy. 18 F-flortaucipir PET alone may convey additional information equivalent to that from amyloid PET. Together with a perfusion-weighted early-phase acquisition ( 18 F-FDG PET-equivalent), a single scan potentially contains comprehensive information on amyloid (A), tau (T), and neurodegeneration (N) status as required by recent biomarker classification algorithms (A/T/N).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hammes, J., Bischof, G. N., Bohn, K. P., Ö, O., Schneider, A., Fliessbach, K., et al. (2021). One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. https://doi.org/10.2967/jnumed.120.244061

Vancouver

Hammes J, Bischof GN, Bohn KP, Ö O, Schneider A, Fliessbach K, et al. One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2021. doi:10.2967/jnumed.120.244061. PMID: 32620704.

BibTeX

@article{hammes2021-32620704,
  author  = {Hammes, J. and Bischof, G. N. and Bohn, K. P. and Ö, Onur and Schneider, A. and Fliessbach, K. and Hönig, M. C. and Jessen, F. and others},
  title   = {{One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases}},
  journal = {Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year    = {2021},
  doi     = {10.2967/jnumed.120.244061},
  pmid    = {32620704},
  url     = {https://doi.org/10.2967/jnumed.120.244061}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record lists 35 participants. Ask whether that is enough for the question, and who they were.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Pattern expression strengths predicted amyloid status with a sensitivity of 0.94 and a specificity of 0.83.
A support vector machine classification based on pattern expression strengths in 2 different SSM/PCA components yielded a prediction accuracy of 98%.
Anatomically, prediction performance was driven by parietooccipital gray matter in amyloid-positive patients versus predominant white matter binding in amyloid-negative patients.
SSM/PCA-derived binding patterns of 18 F-flortaucipir differentiate between amyloid-positive and -negative neurodegenerative diseases with high accuracy. 18 F-flortaucipir PET alone may convey additional information equivalent to that from amyloid PET.
Together with a perfusion-weighted early-phase acquisition ( 18 F-FDG PET-equivalent), a single scan potentially contains comprehensive information on amyloid (A), tau (T), and neurodegeneration (N) status as required by recent biomarker classification algorithms (A/T/N).

Why it matters

A single flortaucipir PET scan distinguished amyloid-positive from amyloid-negative neurodegenerative disease with high accuracy, and the authors suggest it may also provide information on amyloid, tau and neurodegeneration status. This concerns diagnosis only and does not treat, cure or prevent Alzheimer's disease.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants35
Evidence strengthLow

How this study scored 46/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of nuclear medicine : official publication, Society of Nuclear Medicine)
Journal's citation record	2 / 4	Journal of Nuclear Medicine: journal h-index 230 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	3 / 5	2021 — within 6 year(s) of the newest study here
Sample size	1 / 4	35 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	3 / 7	Cited 36 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	5.1 citations a year over 7 year(s) since 2021
Impact for its field and year	3 / 6	Cited 3.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 2 other studies in this library
Still being cited	2 / 4	Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Thilo van Eimeren: h-index 50 (OpenAlex, whole career)
Institution's track record	1 / 3	University of Bonn: institution h-index 1,072 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 9 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 32620704)
Free to read	0 / 2	Behind a paywall — scores zero
Total	46 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Biomarkers from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →